When Maria Thompson's newborn daughter failed the routine heel prick test, she expected to hear those words every new parent dreads. "I think you always believe it's never going to happen to me," she said.
Maria's story is not unusual. Across the United Kingdom, thousands of babies undergo the newborn blood spot test—commonly called the heel prick test—every year. The test checks for rare genetic conditions that, if caught early, can be treated before they cause serious harm. For most families, the results come back clear. But for some, a positive result means more tests are needed.
Now, UK researchers are studying how to make that moment easier for parents like Maria.
The heel prick test has transformed children's lives by finding serious but treatable conditions before symptoms even appear, according to academics writing in The Conversation. The test looks for conditions including cystic fibrosis, sickle cell disease, and spinal muscular atrophy—a condition that weakens muscles and gets worse over time. When caught early, treatments can make a real difference.
But here's the challenge: most parents have no family history of these rare conditions. They never imagined their seemingly healthy baby could be affected. The test happens in the chaotic first days after birth, when parents are exhausted and overwhelmed. It can feel like just another thing "everyone does" at the hospital—until the results suggest otherwise.
"A complete bolt from the blue" is how one parent described receiving a positive result. The screening reverses the normal way we learn something is wrong. Usually, symptoms appear first, then parents seek help. With newborn screening, the possibility of a condition comes before any signs of illness.
Researchers at UK universities have been interviewing parents to understand what helps—and what doesn't—when families receive news that something might be wrong. Their findings offer practical guidance for doctors and nurses.
One key finding: parents prefer to hear results together, so both caregivers receive the same information at the same time. Nobody wants to be the one who has to relay complicated, frightening news to their partner. Parents also want to speak with someone who knows about the specific condition—not just someone who can read a form. Even if it takes slightly longer to arrange, talking to a specialist who can answer questions, explain what happens next, and admit what they don't yet know helps reduce anxiety.
Doctors, meanwhile, face a tricky balance. They must give parents enough information to understand the results and make decisions, without overwhelming families who are already distressed. Structured approaches to these conversations can help clinicians find that balance.
The researchers emphasize that a positive screening result is not a diagnosis—it's the start of a process. More tests are usually needed before anyone can say for certain whether a baby has the condition. But understanding that distinction in the emotional fog after giving birth can be hard.
As newborn screening programs expand to include more conditions, these communication challenges are becoming more urgent. The hope is that better conversations now will mean less distress for families later—and that babies who need treatment will get it as quickly as possible.